Cargando…
Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
OBJECTIVE: The aim of this study is twofold. First, to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the “treat-and-extend regimen” (TER) in patients with neovascular age-related macular degeneration (nAMD). Second, to det...
Autores principales: | Jaki Mekjavic, Polona, Zaletel Benda, Polona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938349/ https://www.ncbi.nlm.nih.gov/pubmed/29765959 http://dx.doi.org/10.3389/fmed.2018.00125 |
Ejemplares similares
-
Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia
por: Jaki Mekjavić, Polona, et al.
Publicado: (2018) -
One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022) -
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023) -
A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017) -
Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)